Thanks for your insightful response TB.
For my part, I don't necessarily agree that the present share price dictates takeover price or timing. The share price is determined by the aggregate supply and demand for the stock at a given time. As others have suggested, I think it's likely that some profit-taking occurred after the Pitt Hopkins readout by those exiting before the Angelman results and longer-term developments. Regardless of the cause, the effect of that selling was to lower the share price.
On the other hand, a competitive takeover price is determined by the willingness to pay of the suitor(s) and the willingness to sell of the target. Given NNZ-2591's potential, as proved up by two positive Phase 2 trial results and preclinical studies in other indications, I do not think suitors will feel constrained by the present share price. They will simply express a willingness to pay which reflects some discount on their expected return from Daybue and NNZ-2591. If there is more than one potential suitor, things get more interesting in an auction-style bidding process.
That still leaves open the question of whether Neuren should court takeover interest now or expend some of its war chest getting NNZ-2591 FDA approval-ready first. Jon/management have not given an explicit indication of their preference, but my sense (speculation only) is that they are hoping to put a bow on the company this year.
Keen to hear what others think.
- Forums
- ASX - By Stock
- Pipeline-in-a-drug
Thanks for your insightful response TB.For my part, I don't...
-
-
- There are more pages in this discussion • 177 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$19.22 |
Change
-0.280(1.44%) |
Mkt cap ! $2.468B |
Open | High | Low | Value | Volume |
$19.50 | $19.59 | $19.19 | $3.259M | 168.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 128 | $19.20 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.22 | 161 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 83 | 19.290 |
4 | 256 | 19.280 |
6 | 335 | 19.270 |
5 | 446 | 19.260 |
5 | 1319 | 19.250 |
Price($) | Vol. | No. |
---|---|---|
19.310 | 75 | 3 |
19.320 | 512 | 8 |
19.330 | 416 | 7 |
19.340 | 255 | 5 |
19.350 | 442 | 5 |
Last trade - 14.10pm 10/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online